ASX healthcare stock Clarity Pharmaceuticals Ltd (ASX: CU6) enjoyed a strong rise of 6.7% yesterday.
Investors reacted positively after the company released a clinical trial update.
Yesterday's rise was good news for the ASX healthcare stock, after experiencing volatility in 2026.
Image source: Getty Images
Company overview and trial update
Clarity Pharmaceuticals specialises in the development of Targeted Copper Theranostics (TCT) for the imaging and treatment of selected cancers.
In particular the company works on identification of certain cancer biomarkers. They develop technology to target those biomarkers with either small molecules or monoclonal antibodies.
Yesterday, the company announced that its registrational Phase III AMPLIFY clinical trial has exceeded its original enrolment target.
The study is evaluating the diagnostic performance of the company's 64Cu-SAR-bisPSMA PET imaging agent in detecting recurrent prostate cancer in men with rising prostate-specific antigen (PSA) levels after initial treatment.
Due to strong demand from clinical trial sites in the United States and Australia, more participants consented than planned. Enrolment has now closed while final screening and participant numbers are confirmed.
The trial will assess imaging at two timepoints – on the day of administration and about 24 hours later.
Results are expected to support a future application to the US Food and Drug Administration (FDA) for approval of the imaging agent.
What did Bell Potter have to say?
In a report from the broker yesterday, Bell Potter said the task ahead is to match the results from the imaging with the standard of truth in order to determine the rate of true positives (TP).
Essentially, the AMPLIFY study has completed enrolment of 220 men with suspected biochemical recurrence of prostate cancer after prostate removal.
All imaging used 64Cu-SAR-bisPSMA and is now finished and awaiting comparison with biopsy and conventional imaging. This will determine the true positive detection rate.
If the agent exceeds the required sensitivity threshold – something current PSMA imaging agents have not achieved – it could uniquely include positive predictive value on its label. This would potentially change treatment guidelines and prove a strong competitive advantage in early-stage recurrence detection.
The inclusion of the positive predictive value on the label would be unique to 64Cu-SAR-bisPSMA and most likely warrant a change to treatment guidelines, particularly for early stage BCR. This would be a clear, sustainable competitive advantage for both utilisation and pricing.
There should be no doubt that 64Cu-SAR-bisPSMA has far better sensitivity for the detection of early stage BCR in mCRPC. The longer isotope half-life, dual PSMA targeting moiety and superior chemistry are underlying drivers for this breakthrough science.
As a result, the broker has retained its speculative buy recommendation and price target of $6.40.
Based on yesterday's closing price of $3.51, this indicates an upside of 82.3% for the ASX healthcare stock.
